The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 501–600 of 1,000
Lewiecki, E. M., Betah, D., Humbert, L., Libanati, C. R., Oates, M. K., Shi, Y., Winzenrieth, R., Ferrari, S., & Omura, F. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae028 · Cited by 25
Self-citationMikula, A. L., Lakomkin, N., Hamouda, A. M., Everson, M. C., Pennington, Z. A., Kumar, R. R., Pinter, Z. W., Martini, M. L., Bydon, M., Kennel, K. A., et al. (2024) · Journal of Neurosurgery Spine · doi:10.3171/2024.4.spine2424 · Cited by 24
Liu, Y., Song, L., Ma, D., Lv, F., Xu, X., Wang, J., Xia, W., Jiang, Y., Wang, O., Song, Y., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.07.012 · Cited by 26
Lhaneche, L., Hald, J. D., Domingues, A., Hannouche, D., Délepine, M., Zélénika, D., Boland, A., Ostertag, A., Cohen-Solal, M. E., Langdahl, B. L., et al. (2016) · Bone · doi:10.1016/j.bone.2016.08.004 · Cited by 24
Self-citationPark, Y. E., Musson, D. S., Naot, D., & Cornish, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.001 · Cited by 26
Cremers, S., & Aronson, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13331 · Cited by 25
Anabolic Strategies to Augment Bone Fracture Healing
Roberts, S. J., & Ke, H. Z. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0440-1 · Cited by 28
Stroncek, J. D., Shaul, J. L., Favell, D., Hill, R. S., Huber, B. M., Howe, J. G., & Bouxsein, M. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24239 · Cited by 25
Experimental agents to improve fracture healing: utilizing the WNT signaling pathway
Haffner‐Luntzer, M. (2020) · Injury · doi:10.1016/j.injury.2020.11.051 · Cited by 26
The canonical Wnt/β-catenin pathway: From the history of its discovery to clinical application
Grebennikova, T. A., Belaya, Z. E., Rozhinskaya, L. Y., & Mel'nichenko, G. A. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688674-81 · Cited by 27
Touw, W. A., Ueland, T., Bollerslev, J., Schousboe, J. T., Lim, W. H., Wong, G., Thompson, P. L., Kiel, D. P., Prince, R. L., Rivadeneira, F., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1040 · Cited by 24
Wu, C., Hung, W., Chang, I., Tsai, T., Chang, Y., McCloskey, E. V., Watts, N. B., McClung, M. R., Huang, C., Chen, C., et al. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100729 · Cited by 25
Self-citationInose, H., Ariga, A., Motoyoshi, T., Fukushima, K., Tomizawa, S., Kato, T., Takahashi, K., Yoshii, T., & Okawa, A. (2022) · JBMR Plus · doi:10.1002/jbm4.10637 · Cited by 24
Hou, J., Su, H., Kuang, X., Qin, W., Liu, K., Pan, K., Zhang, B., Yang, S., Yang, S., Xiao, P., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.922070 · Cited by 25
Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
Kaneuchi, Y., Iwabuchi, M., Hakozaki, M., Yamada, H., & Konno, S. (2022) · Medicina · doi:10.3390/medicina59010019 · Cited by 23
The Eucalcemic Patient With Elevated Parathyroid Hormone Levels
Shaker, J. L., & Wermers, R. A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad013 · Cited by 28
Appropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
Cejka, D., Parada-Rodriguez, D., Pichler, S., Marculescu, R., Krämer, I., Kneissel, M., Gross, T. J., Reisinger, A., Pahr, D. H., Monier‐Faugere, M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.019 · Cited by 23
Boltenstål, H., Qureshi, A. R., Behets, G. J. S., Lindholm, B., Stenvinkel, P., D’Haese, P. C., & Haarhaus, M. L. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0491-4 · Cited by 23
Xu, Y., Gao, C., He, J., Gu, W., Yi, C., Chen, B., Wang, Q., Tang, F. R., Xu, J.-L., Yue, H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00057 · Cited by 26
Osteoporosis Therapeutics 2020
Kocijan, R., Klaushofer, K., & Misof, B. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_373 · Cited by 26
Fracture risk estimation may facilitate the treatment gap in osteoporosis
Lems, W. F. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208245 · Cited by 23
Mochizuki, T., Yano, K., Ikari, K., & Okazaki, K. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.08.001 · Cited by 22
Miyauchi, A., Hamaya, E., Nishi, K., Tolman, C., & Shimauchi, J. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01332-8 · Cited by 22
EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Osteoporosis management
Reid, I. R. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0574 · Cited by 23
B4GALNT3 regulates glycosylation of sclerostin and bone mass
Movérare‐Skrtic, S., Voelkl, J. G. J., Nilsson, K. H., Nethander, M., Luong, T. T. D., Alesutan, I., Li, L., Wu, J., Horkeby, K., Lagerquist, M. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104546 · Cited by 24
Bisphosphonates and glucocorticoid-induced osteoporosis: cons
Lems, W. F., & Saag, K. G. (2015) · Endocrine · doi:10.1007/s12020-015-0639-1 · Cited by 25
Emerging drugs for osteoporosis
Feurer, E., & Chapurlat, R. D. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.936377 · Cited by 24
Evaluating and mitigating fracture risk in established rheumatoid arthritis
Mullen, M. B., & Saag, K. G. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.09.005 · Cited by 27
Smad4 is required to inhibit osteoclastogenesis and maintain bone mass
Morita, M., Yoshida, S., Iwasaki, R., Yasui, T., Sato, Y., Kobayashi, T., Watanabe, R., Oike, T., Miyamoto, K., Takami, M., et al. (2016) · Scientific Reports · doi:10.1038/srep35221 · Cited by 23
Janeczek, A. A., Scarpa, E., Horrocks, M. H., Tare, R. S., Rowland, C. A., Jenner, D. C., Newman, T. A., Oreffo, R. O. C., Lee, S. F., & Evans, N. D. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0386 · Cited by 22
Midha, S., Chameettachal, S., Dey, E., & Ghosh, S. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00006 · Cited by 22
Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii
Nguyen, E. T., Posas-Mendoza, T., Siu, A., Ahn, H. J., Choi, S. Y., & Lim, S. Y. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4553-2 · Cited by 22
Autophagy: A Promising Target for Age-related Osteoporosis
Wang, T., He, H., Liu, S., Jia, C., Fan, Z., Zhong, C., Yu, J., Liu, H., & He, C. (2018) · Current Drug Targets · doi:10.2174/1389450119666180626120852 · Cited by 24
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Yongyun, C., Jingwei, Z., Liu, Z., Chu, W., & Li, H. (2019) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2019.02.001 · Cited by 22
Kalousová, M., Sulková, S., Kuběna, A. A., Zakiyanov, O., Tesař, V., & Zima, T. (2019) · Physiological Research · doi:10.33549/physiolres.934034 · Cited by 22
Albiol, L., Büttner, A., Pflanz, D., Mikolajewicz, N., Birkhold, A., Krämer, I., Kneissel, M., Duda, G. N., Checa, S., & Willie, B. M. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00648-4 · Cited by 26
Wei, Q., Wang, B., Hu, H., Xie, C., Long, L., Gao, J., & Cao, Y. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4470 · Cited by 26
Androjna, C., Yee, C. S., White, C. R., Waldorff, E. I., Ryaby, J. T., Zborowski, M., Alliston, T. N., & Midura, R. J. (2020) · Bone · doi:10.1016/j.bone.2020.115761 · Cited by 22
Osteoporosis in the at-risk asthmatic
Aljubran, S. A., Whelan, G. J., Glaum, M. C., & Lockey, R. F. (2014) · Allergy · doi:10.1111/all.12438 · Cited by 23
Gerbaix, M., Ammann, P., & Ferrari, S. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4193 · Cited by 21
Anabolic treatments for osteoporosis in postmenopausal women
Hassan, N., Gregson, C. L., & Tobias, J. H. (2021) · Faculty Reviews · doi:10.12703/r/10-44 · Cited by 23
Hsu, C., Maddox, J., Block, G. A., Bartley, Y., & Yu, Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2050 · Cited by 21
Self-citationEndocrine functions of sclerostin
Riddle, R. C. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100433 · Cited by 23
Huang, W., Nagao, M., Yonemoto, N., Guo, S., Tanigawa, T., & Nishizaki, Y. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5594 · Cited by 22
Τhe story of sclerostin inhibition: the past, the present, and the future
Anastasilakis, A. D., & Tsourdi, E. A. (2024) · HORMONES · doi:10.1007/s42000-023-00521-y · Cited by 22
Hartz, M. C., Johannessen, F. B., Harsløf, T., & Langdahl, B. L. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae484 · Cited by 21
Self-citationChallenges for the Development of Bone-Forming Agents in Europe
Kanis, J. А., Rizzoli, R., Cooper, C. C., & Reginster, J. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9844-9 · Cited by 21
Self-citationZhang, Y., Feng, E., Xu, Y. J., Wang, W., Zhang, T., Xiao, L., Chen, R., Lin, Y., Chen, D., Lin, L., et al. (2015) · PubMed · Cited by 21
Mohan, G., Lay, E. Y.-A., Berka, H., Ringwood, L. A., Kot, A., Chen, H., Yao, W., & Lane, N. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0195-6 · Cited by 21
Cao, Y., Wang, B., Wang, D., Zhan, D., Mai, C., Wang, P., Wei, Q., Liu, Y., Wang, H., He, W., et al. (2019) · International Journal of Genomics · doi:10.1155/2019/7076513 · Cited by 24
SOST Deficiency Aggravates Osteoarthritis in Mice by Promoting Sclerosis of Subchondral Bone
Li, J., Xue, J., Jing, Y., Wang, M., Shu, R., Xu, H., Xue, C., Feng, J., Wang, P., & Bai, D. (2019) · BioMed Research International · doi:10.1155/2019/7623562 · Cited by 25
Drug treatment strategies for osteoporosis in stroke patients
Hsieh, C., Sung, S., & Huang, H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1736556 · Cited by 22
Nealy, K. L., & Harris, K. B. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020952764 · Cited by 23
Epigenetic therapies of osteoporosis
de Nigris, F., Ruosi, C., Colella, G., & Napoli, C. (2020) · Bone · doi:10.1016/j.bone.2020.115680 · Cited by 23
Controversies in the use of new bone‐modifying therapies in multiple myeloma
Terpos, E., & Ntanasis‐Stathopoulos, I. (2020) · British Journal of Haematology · doi:10.1111/bjh.17256 · Cited by 21
Jeong, C., Kim, J., Lim, Y., Ha, J., Kang, M. I., & Baek, K. (2021) · Journal of Bone Metabolism · doi:10.11005/jbm.2021.28.4.317 · Cited by 21
Bastounis, A., Langley, T. E., Davis, S., Paskins, Z., Gittoes, N. J. L., Leonardi‐Bee, J., & Sahota, O. (2022) · JBMR Plus · doi:10.1002/jbm4.10620 · Cited by 22
Nickolas, T. L., & Jamal, S. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9314-3 · Cited by 21
Li, Y., Hamang, M., Lucchesi, J., Bivi, N., Zeng, Q., Adrian, M. D., Raines, S. E., Li, J., Kuhstoss, S. A., Obungu, V. H., et al. (2016) · Bone · doi:10.1016/j.bone.2016.12.003 · Cited by 22
Li, C., Wang, J., Niu, Y., Zhang, H., Ouyang, H., Zhang, G., & Fu, Y. S. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c20946 · Cited by 23
Sangadala, S., Kim, C. H., Fernandes, L. M., Makkar, P., Boden, S. D., Beck, G. R., Drissi, H., & Presciutti, S. M. (2023) · eLife · doi:10.7554/elife.63402 · Cited by 22
Surgical Management of Adult Spinal Deformity Patients with Osteoporosis
Baroudi, M., Daher, M., Maheshwari, K., Singh, M., Nassar, J. E., McDonald, C. L., Diebo, B. G., & Daniels, A. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237173 · Cited by 20
Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab
Reid, I. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0229-2 · Cited by 23
Fulzele, K. S., Dedic, C., Lai, F., Bouxsein, M., Lotinun, S., Baron, R., & Pajevic, P. D. (2018) · Bone · doi:10.1016/j.bone.2018.09.021 · Cited by 20
Romosozumab in the Treatment of Osteoporosis
Kobza, A. O., Παπαϊωάννου, Α., Lau, A. N., & Adachi, J. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0158 · Cited by 20
Waitupu, A., Pratiwi, L., Sutanto, H., Santoso, D., & Hertanto, D. M. (2025) · Experimental Physiology · doi:10.1113/ep092401 · Cited by 21
Sawakami, K., Watanabe, K., Hasegawa, K., Yamamoto, N., Shimakura, T., Ohashi, M., Shoji, H., Mizouchi, T., Tanaka, Y., Segawa, H., et al. (2021) · Journal of Neurosurgery Spine · doi:10.3171/2021.5.spine202003 · Cited by 20
Examining the role of cannabinoids on osteoporosis: a review
Clouse, G., Penman, S. L., Hadjiargyrou, M., Komatsu, D. E., & Thanos, P. K. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01190-x · Cited by 21
Position Statement: Vitamin D Intake to Prevent Osteoporosis and Fracture in Adults
Han, A., Park, Y., Lee, Y., Park, S. Y., & Park, C. Y. (2022) · Journal of Bone Metabolism · doi:10.11005/jbm.2022.29.4.205 · Cited by 22
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery
Krebs, K., & Milani, L. A. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051421-111324 · Cited by 20
Hu, M., Zhang, Y., Guo, J., Guo, C., Yang, X., Ma, X., Xu, H., & Xiang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1188969 · Cited by 20
Ebina, K., Nagayama, Y., Kashii, M., Tsuboi, H., Okamura, G., Miyama, A., Etani, Y., Noguchi, T., Hirao, M., Miura, T., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07019-2 · Cited by 19
Tripto‐Shkolnik, L., Szalat, A., Tsvetov, G., Rouach, V., Sternberg, C., Hoppe, A., Burshtein, G., Galitzer, H., Toledano, M., Harari, G., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae057 · Cited by 20
Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
Kobayashi, T., Hara, M., Shimanoe, C., Morimoto, T., Mawatari, M., Ito, K., & Shimazaki, T. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01531-5 · Cited by 19
Wong, R. M. Y., Wong, P. Y., Liu, C., Wong, H. Y., Fong, M. K., Zhang, N., Cheung, W., & Law, S. W. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.07.011 · Cited by 22
Sclerostin: recent advances and clinical implications
Honasoge, M., Rao, A. D., & Rao, S. D. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000114 · Cited by 26
Schoeman, M. A. E., Moester, M. J. C., Oostlander, A. E., Kaijzel, E. L., Valstar, E. R., Nelissen, R. G. H. H., Löwik, C. W. G. M., & de Rooij, K. E. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25241 · Cited by 21
Thouverey, C., & Caverzasio, J. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.126 · Cited by 20
Value of Osteoblast-Derived Exosomes in Bone Diseases
Ge, M., Wu, Y., Ke, R., Cai, T., Yang, J., & Mu, X. (2017) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000003463 · Cited by 19
Shatunova, E. A., Korolev, M. A., Omelchenko, V. O., Kurochkina, Y. D., Davydova, A., Venyaminova, A. G., & Vorobyeva, M. (2020) · Biomedicines · doi:10.3390/biomedicines8110527 · Cited by 23
Fujiwara, M., Kubota, T., Wang, W. J., Ohata, Y., Miura, K., Kitaoka, T., Okuzaki, D., Namba, N., Michigami, T., Kitabatake, Y., et al. (2016) · Bone · doi:10.1016/j.bone.2016.01.024 · Cited by 19
López-Delgado, L., Riancho‐Zarrabeitia, L., & Riancho, J. A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1154533 · Cited by 19
Leder, B. Z., Ramchand, S. K., Jordan, M., Ryan, S., Patnaik, A., Lee, H., & Tsai, J. N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00319-5 · Cited by 18
Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
Cardinal, M., Chretien, A., Roels, T., Lafont, S., Ominsky, M. S., Devogelaer, J., Manicourt, D. H., & Behets, C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.705505 · Cited by 21
Osteoanabolic therapy for osteoporosis in women
McClung, M. R., & Clark, A. (2021) · Climacteric · doi:10.1080/13697137.2021.1953463 · Cited by 20
Self-citationThe role of osteoanabolic agents in the management of patients with osteoporosis
McClung, M. R., Rothman, M. S., Lewiecki, E. M., Hanley, D. A., Harris, S. T., Miller, P. D., & Kendler, D. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2069582 · Cited by 20
Self-citationLim, S. Y., & Bolster, M. B. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s315184 · Cited by 22
Han, Y., Mo, Y.-Y., Wu, H., Iqbal, J., Cai, J., Li, L., Bu, Y., Xiao, F., Jiang, H., Wen, Y., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102425 · Cited by 19
Regulatory cellular and molecular networks in the bone microenvironment during aging
Zhang, L., Wang, Z., Zhang, Y., Ji, R., Li, Z., Zou, J., & Gao, B. (2024) · Life Medicine · doi:10.1093/lifemedi/lnae019 · Cited by 22
Amrein, K., Dobnig, H., Wagner, D., Piswanger-Soelkner, C., Pieber, T. R., Pilz, S., Tomaschitz, A., Dimai, H. P., & Fahrleitner‐Pammer, A. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12791 · Cited by 20
Sugiyama, T., Torio, T., Miyajima, T., Kim, Y. T., & Oda, H. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00054 · Cited by 18
Jakob, F. J., Genest, F., Baron, G., Stumpf, U., Rudert, M., & Seefried, L. (2015) · Der Unfallchirurg · doi:10.1007/s00113-015-0085-9 · Cited by 23
Emerging anabolic agents in the treatment of osteoporosis
Lovato, C. M., & Lewiecki, E. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362389 · Cited by 18
Takahashi, A., Mulati, M., Saito, M., Numata, H., Kobayashi, Y., Ochi, H., Sato, S., Kaldis, P., Okawa, A., & Inose, H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004834 · Cited by 18
Shimizu, T., Arita, K., Murota, E., Hiratsuka, S., Fujita, R., Ishizu, H., Asano, T., Takahashi, D., Takahata, M., & Iwasaki, N. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01226-1 · Cited by 18
Geusens, P., Feldman, R., Oates, M. K., Thomas, T., Makras, P., Jakob, F. J., Langdahl, B. L., Wang, Z., Rojeski, M., & Libanati, C. R. (2021) · Bone · doi:10.1016/j.bone.2021.116209 · Cited by 22
Self-citationOsteochemonecrosis: An Overview
Hellstein, J. W. (2014) · Head and Neck Pathology · doi:10.1007/s12105-014-0583-z · Cited by 20
Nicol, L. E., Wang, Y., Smith, R. C., Sloan, J. H., Nagamani, S. C. S., Shapiro, J. R., Lee, B., & ORWOLL, E. S. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3312 · Cited by 19
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.